Intellia Therapeutics Stock (NASDAQ: NTLA)

Intellia Therapeutics

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Cathie Wood Smelling AI Opportunity? Ark Invest Buys Tempus AI Dip, Scoops Up Over $13 M Worth Of Stock

Equities

News

Markets

ETFs

ARKF

ARKG

ARKK

ARKW

CDNA

GTLB

IBTA

NTLA

PATH

PRME

RBLX

RPTX

Ark Invest&#39;s Cathie Wood-led funds made significant trades involving GitLab, Intellia, Prime Medicine, UiPath, Ibotta, Roblox, Repare Therapeutics, and CareDx.

Cathie Wood&#39;s Ark Invest Continues To Offload UiPath, Roblox: Loads Up On GitLab, Ibotta

xr:d:DAFq8R_nQ7g:2,j:6031844861216095376,t:23080809

Downgrades

Pre-Market Outlook

Analyst Ratings

Trading Ideas

PLUG

This RingCentral Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Oct,15,,2019,Sunnyvale, - ,Ca, - ,Usa,-,Close

Price Target

EXEL

PTLO

QRVO

TWLO

Abbott To Rally Over 26%? Here Are 10 Top Analyst Forecasts For Monday

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics Inc

Legal

Press Releases

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA

Small Cap

NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA

The Gross Law Firm Reminds Intellia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA

Investors who lost money on Intellia Therapeutics, Inc.(NTLA) should contact The Gross Law Firm about pending Class Action - NTLA

Shareholders that lost money on Intellia Therapeutics, Inc.(NTLA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

Investors in Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights – NTLA

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

CareDx

Chimerix

Cogent Biosciences

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

89bio

Geron

GRAIL

Gyre Therapeutics

Immunome

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

MiMedx Group

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Myriad Genetics

Nurix Therapeutics

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Arcus Biosciences

Replimune Group

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Spyre Therapeutics

Vir Biotechnology

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Xencor

Zymeworks

HC Wainwright & Co.

Truist Securities

Barclays

Citigroup

Wells Fargo

Comments

Intellia Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga